In quiet hospital corridors, a microscopic arms race is unfolding, forcing doctors to rethink how they hunt down dangerous infections.
Across the UK, hospitals are starting to use rapid DNA sequencing to track antibiotic‑resistant “superbugs” in real time, reshaping how infections are diagnosed and contained.
A race against time inside the hospital
Antibiotic‑resistant infections already kill tens of thousands of people worldwide every year. They also keep patients in hospital longer, consume intensive care beds and drain already stretched budgets.
Traditional microbiology often leaves doctors waiting days for results. In difficult cases, cultures stay stubbornly negative, even as the patient’s condition worsens. That leaves clinicians prescribing broad‑spectrum antibiotics “just in case”, which fuels resistance further.
Rapid DNA sequencing can now identify the culprit bacteria from a clinical sample in under 48 hours, even when standard cultures find nothing.
A new study from Barts Health NHS Trust and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), published in the journal Frontiers in Cellular and Infection Microbiology, shows how this technology can plug that gap. The work focuses on a specific genetic target called the 16S ribosomal RNA gene, found in almost all bacteria.
How rapid DNA sequencing works on the ward
Instead of trying to grow bacteria on a plate, the new method goes straight to the genetic code. Lab teams extract all the DNA from a patient sample – spinal fluid, bone tissue, joint fluid or other material from normally sterile parts of the body.
They then amplify regions of the 16S gene, which acts like a barcode for bacteria. Using portable devices from Oxford Nanopore Technologies (ONT), such as the MinION, the lab reads these barcodes in real time.
Sequencing the full 16S gene, rather than just short fragments, allows a much more precise ID of which species – or combination of species – is present.
The researchers targeted two regions of the gene, known as V1‑V2 and V1‑V9, to cover a broader stretch of bacterial DNA and boost sensitivity. Bioinformatics software then compares the sequences obtained with reference databases and reports back which organisms are present.
➡️ Satellites detect titanic 35‑metre waves in the middle of the Pacific
➡️ Goodbye to grey hair : the trick to add to your shampoo to revive and darken your hair
➡️ Mocha mousse hair dye: subtle highlights for natural brunettes
➡️ Excess rainfall could remake the Sahara and upset Africa’s fragile balance, study warns
Standardisation: the unglamorous piece that makes it work
This kind of “metagenomic” testing has existed for years, but usually only in research labs. The problem was that every hospital used its own mix of reagents, settings and analysis tools. Results from one lab could be hard to compare with results from another.
The Barts and MHRA team tried to fix that by building a standardised protocol designed specifically for routine NHS use. They worked with the National Measurement Laboratory and the MHRA, which serves as a collaborating centre for the World Health Organization, to create reference materials.
These materials are carefully calibrated mixtures of clinically relevant bacteria. Labs run them through the full pipeline – DNA extraction, amplification and sequencing – to check that each step is working properly and consistently.
This push for standardisation is key to gaining ISO 15189 accreditation, the quality badge that clinical laboratories need before a new test can become routine.
Putting the technology to the test on real patients
The study validated the method using 34 complex samples from hospitalised patients with serious infections. All came from normally sterile sites, including:
- cerebrospinal fluid in suspected meningitis cases
- bone samples from deep bone infections
- joint fluids taken during suspected septic arthritis
Many of these patients had already received antibiotics before sampling. That often wipes out live bacteria and makes cultures negative, even though infection is still present. Standard Sanger sequencing of short 16S fragments had also failed to give clear results in several cases.
With the nanopore‑based method, the team identified at least one pathogen in every single sample, including all 12 that were negative using previous Sanger 16S PCR. The long reads – up to about 1,500 DNA base pairs – covered nearly the full gene, giving much clearer species‑level resolution.
Mixed infections, where more than one bacterial species is involved, emerged as a particularly strong point. These are notoriously hard to pick up with classic approaches, which tend to highlight whichever organism grows fastest in culture.
What this means in practice for clinicians
For frontline staff, the biggest change is speed and confidence. Instead of waiting several days and often getting “no growth” on culture, they can receive a genetic report within about two days:
| Step | Approximate timing |
|---|---|
| Sample collection and transport to lab | 0–6 hours |
| DNA extraction and 16S amplification | 6–24 hours |
| Nanopore sequencing run | 4–12 hours |
| Bioinformatics analysis and reporting | 6–12 hours |
That timeline means decisions about antibiotics can be based on evidence while the patient is still in a critical window, instead of being locked into broad, empiric therapy.
Targeted antibiotics against superbugs
Once the causative bacteria are known, doctors can cross‑reference this with local resistance data or run targeted susceptibility tests. That allows them to narrow treatment quickly – switching from a cocktail of high‑end antibiotics to a focused regimen tailored to the intruder.
Shorter, targeted courses of antibiotics mean fewer side effects for patients and less selection pressure driving resistance across the hospital.
From a public health perspective, the gains are cumulative. Each time a hospital can avoid a week‑long course of broad‑spectrum drugs, it reduces opportunities for new resistant strains to emerge or spread.
The genetic data can also be used for outbreak tracking. If the same strain appears in several patients on the same ward, infection control teams get an early warning that something, somewhere – a sink, a ventilator circuit, a shared device – may be acting as a reservoir.
A strategic shift in the fight against hospital-acquired infections
Hospital‑acquired infections, or nosocomial infections, hit already vulnerable patients: those on chemotherapy, intensive care, or recovering from surgery. When a multidrug‑resistant organism takes hold in these settings, every lost hour raises the stakes.
By adding rapid sequencing to their toolkit, hospitals move from reactive fire‑fighting to proactive surveillance.
- Suspicious cases can be investigated even when cultures fail.
- Hidden reservoirs of bacteria can be mapped through genetic fingerprints.
- Antibiotic policies can be adjusted based on real‑time data, not last year’s audit.
For national health systems, this shift could help hold back what some experts describe as a slow‑motion pandemic of resistant infections, where routine surgery becomes risky and common procedures like hip replacements carry serious infection dangers.
What patients and staff should know about the technology
Rapid sequencing does not replace existing tests overnight. Blood cultures, standard swabs and routine microbiology remain the first line in many situations because they are cheap, familiar and widely available.
Instead, 16S sequencing is likely to be used where the stakes are high and standard tests fail. Think of a patient with suspected brain infection, deteriorating quickly, but with repeated negative cultures. Or a child with a mysterious joint infection that is not responding to standard antibiotics.
In these “grey zone” cases, a genetic answer – even if it arrives one or two days later – can change the whole trajectory of care.
There are limits. The method focuses on bacteria, so it does not pick up viruses or fungi. Contamination is a constant concern: even tiny amounts of environmental DNA can confuse results if labs do not follow strict protocols. Interpretation also needs experienced clinicians, as the detection of a bacterium does not always mean it is the true cause of disease.
Key terms worth unpacking
Superbugs are bacteria that have become resistant to multiple antibiotics. They are not more “aggressive” by nature, but they are much harder to treat because the usual drugs do not work. Some well‑known examples include MRSA and certain strains of Escherichia coli and Klebsiella.
16S rRNA gene is a segment of DNA that forms part of the machinery bacteria use to make proteins. It contains regions that are almost identical across all bacteria, and other regions that vary between species. That combination makes it a powerful barcode for identification.
Nanopore sequencing is a technique where DNA strands are passed through tiny holes, or nanopores, in a membrane. As each base moves through, it changes an electrical signal, which the device interprets as a sequence of letters. The equipment is small and can sit on a benchtop, which is why it appeals to hospital labs.
What the future may look like on a typical ward
Imagine a respiratory ward during winter. Several patients with chronic lung disease spike fevers. Standard tests find a range of bacteria, but one patient does unusually badly, and cultures are negative. A rapid sequencing test on their sputum reveals a rare, highly resistant strain that standard panels do not pick up easily.
Armed with that information, infection control teams screen nearby patients using targeted methods. They spot two more carriers early, adjust antibiotics for those already infected and step up cleaning and isolation measures. Instead of weeks of unexplained deterioration across the ward, the outbreak is blunted at the start.
Scale that scenario across a country’s hospital network and the impact becomes clearer. Each avoided cluster of resistant infections preserves both individual lives and the long‑term usefulness of existing antibiotics.
For now, these rapid DNA tests are being rolled out in a limited number of centres, often as part of research or pilot programmes. As costs fall and protocols mature, they are likely to spread, quietly reshaping how hospitals think about microbes drifting through their corridors.
Originally posted 2026-03-03 14:46:54.